BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast...

por Dang, Chau, Ewer, Michael S., Delaloge, Suzette, Ferrero, Jean-Marc, Colomer, Ramon, de la Cruz-Merino, Luis, Werner, Theresa L., Dadswell, Katherine, Verrill, Mark, Eiger, Daniel, Sarkar, Sriparna, de Haas, Sanne Lysbet, Restuccia, Eleonora, Swain, Sandra M.
Publicado 2022

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced bre...

por Perez, Edith A., de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H., Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony
Publicado 2019

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positi...

por Perez, Edith A., de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H., Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony
Publicado 2019

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

por Harbeck, Nadia, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Gluz, Oleg
Publicado 2021